KFF is tracking the Medicaid provisions in the 2025 federal budget bill, including new Medicaid work and verification requirements and a reduction in the expansion match rate for states that use their own funds to cover undocumented immigrants.
There is no excerpt because this is a protected post.
Approximately 12 million people are enrolled in both Medicare and Medicaid, referred to as dual-eligible individuals. This brief examines the demographic, socioeconomic, and health characteristics of dual-eligible individuals compared with Medicare beneficiaries without Medicaid.
It is time we realize that there is no single panacea for mental health; the need to break down barriers for working families and individuals in rural towns or underserved communities requires we move past a narrow definition of telehealth. The post The Miscalculation of Teletherapy: Why Digital Mental Health Goes Beyond Virtual Sessions appeared…
In this analysis, published in the journal Contraception, KFF’s Linda Li, Brittni Frederiksen, and Alina Salganicoff look at intrauterine device (IUD) and contraceptive implant insertion-related costs among privately insured individuals to better understand why patients are experiencing unexpected expenses for what should be fully covered contraceptive services under the ACA.
We do not need models that pretend every patient has equal or equitable access to care. We need models capable of recognizing disparities and responding to them. The post Is Bias in Clinical AI Good or Bad? It’s More Complicated Than That appeared first on MedCity News.
Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease. The post FDA Approval Expands Novo Nordisk’s Wegovy to the…
Certified clinicians and therapists have specific ethical foundations and analytic responsibilities to uphold that might not apply to all members of the healthcare field. The post Understanding the Ethics of AI in ABA Therapy appeared first on MedCity News.
This brief examines the implications of rising prescriptions for costly GLP-1 drugs for state Medicaid programs as more states consider covering the drugs for weight loss. It examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.
This analysis examines the latest Monitoring, Evaluation, and Results (MER) data released by the PEPFAR program, the first glimpse of PEPFAR programming and outcomes for FY 2025.